Kalohexis files confidential IPO draft registration with SEC

Kalohexis, Inc., a clinical-stage biotechnology company focused on the melanocortin system for metabolic diseases including obesity and cancer cachexia, has submitted a confidential draft registration statement on Form S-1 to the Securities and Exchange Commission in connection with a proposed initial public offering of its common stock.

The company has not yet determined the number of shares to be offered or the price range for the proposed offering. The IPO is expected to proceed after the SEC completes its review, subject to market and other conditions.

You May Also Be Interested In

• Apnimed files for initial public offering on Nasdaq
• HCC Healthcare signs SPAC deal with RF Acquisition, eyes Nasdaq listing
• FDA clears Merck's Keytruda combo for muscle-invasive bladder cancer